NCT00066729View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 23, 2003

Primary Completion Date

May 9, 2006

Study Completion Date

August 1, 2013

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

NY-ESO-1 peptide vaccine

NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ludwig Institute for Cancer Research

OTHER